Cancerous cells of glioblastoma, the tumor that can start spreading from the brain, are notorious for their resistance to chemotherapies and radiation therapies. But a new study has brought some hope against these glioblastoma-initiating cells, by identifying a new compound that could act to kill these chemotherapy-resistant cells.
Presently known as compound 10580, the new drug was identified by a team of researchers from the collaborative research group between Hokkaido University, FujiFilm Corporation, and the National Institute of Advanced Industrial Science and Technology (AIST). The paper was recently published in the Neuro-Oncology journal. 
“Compound 10580 is a promising candidate for developing drugs against glioblastoma and other recurring cancers. Further technological developments of a drug delivery system or 10580 derivatives, which can cross the blood-brain barrier, are needed,” says Toru Kondo of Hokkaido University’s Institute for Genetic Medicine who led the study. 
Within this research, the compound was tested on tumor-bearing mice. It was orally administered and was found to have “strong anti-cancer efficacy”. It was also noticed to be non-toxic to regular cells.
The results of this study can help with producing drugs that are capable of eradicating refractory tumors with low toxicity.